HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis

Front Immunol. 2024 Jul 10:15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024.

Abstract

Introduction: Genetic predisposition to autoimmune encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDAR) is poorly understood. Given the diversity of associated environmental factors (tumors, infections), we hypothesized that human leukocyte antigen (HLA) and killer-cell immunoglobulin-like receptors (KIR), two extremely polymorphic gene complexes key to the immune system, might be relevant for the genetic predisposition to anti-NMDAR encephalitis. Notably, KIR are chiefly expressed by Natural Killer (NK) cells, recognize distinct HLA class I allotypes and play a major role in anti-tumor and anti-infection responses.

Methods: We conducted a Genome Wide Association Study (GWAS) with subsequent control-matching using Principal Component Analysis (PCA) and HLA imputation, in a multi-ethnic cohort of anti-NMDAR encephalitis (n=479); KIR and HLA were further sequenced in a large subsample (n=323). PCA-controlled logistic regression was then conducted for carrier frequencies (HLA and KIR) and copy number variation (KIR). HLA-KIR interaction associations were also modeled. Additionally, single cell sequencing was conducted in peripheral blood mononuclear cells from 16 cases and 16 controls, NK cells were sorted and phenotyped.

Results: Anti-NMDAR encephalitis showed a weak HLA association with DRB1*01:01~DQA1*01:01~DQB1*05:01 (OR=1.57, 1.51, 1.45; respectively), and DRB1*11:01 (OR=1.60); these effects were stronger in European descendants and in patients without an underlying ovarian teratoma. More interestingly, we found increased copy number variation of KIR2DL5B (OR=1.72), principally due to an overrepresentation of KIR2DL5B*00201. Further, we identified two allele associations in framework genes, KIR2DL4*00103 (25.4% vs. 12.5% in controls, OR=1.98) and KIR3DL3*00302 (5.3% vs. 1.3%, OR=4.44). Notably, the ligands of these KIR2DL4 and KIR3DL3, respectively, HLA-G and HHLA2, are known to act as immune checkpoint with immunosuppressive functions. However, we did not find differences in specific KIR-HLA ligand interactions or HLA-G polymorphisms between cases and controls. Similarly, gene expression of CD56dim or CD56bright NK cells did not differ between cases and controls.

Discussion: Our observations for the first time suggest that the HLA-KIR axis might be involved in anti-NMDAR encephalitis. While the genetic risk conferred by the identified polymorphisms appears small, a role of this axis in the pathophysiology of this disease appears highly plausible and should be analyzed in future studies.

Keywords: DQA1; DQB1; DRB1; HLA; KIR; KIR2DL4; KIR3DL3; anti-NMDAR encephalitis.

MeSH terms

  • Adult
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis* / genetics
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis* / immunology
  • Female
  • Genetic Predisposition to Disease*
  • Genome-Wide Association Study*
  • HLA Antigens* / genetics
  • HLA Antigens* / immunology
  • Humans
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / metabolism
  • Male
  • Middle Aged
  • Receptors, KIR* / genetics
  • Young Adult

Substances

  • Receptors, KIR
  • HLA Antigens

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by research grant NIH-1U01NS120885 (EM). PN is supported by research grant NIH U01AI090905. JH, A-LP, GP, and VR are supported by a public grant overseen by the Agence Nationale de la Recherche (ANR) as part of the “Investissements d’Avenir” program (ANR-18-RHUS-0012), and performed within the framework of the LABEX CORTEX of the Université Claude Bernard Lyon 1, and the program “ Investissements d’Avenir “ (ANR-11-LABX-0042) operated by the ANR. SI was supported by the Wellcome Trust (104079/Z/14/Z), Medical Research Council (MR/V007173/1), BMA Research Grants—Vera Down grant (2013), Margaret Temple (2017), Epilepsy Research UK (P1201), the Fulbright UK-US commission (MS Society research award), the NIHR Oxford Biomedical Research Centre, and by the Wellcome Trust (Grant number 104079/Z/14/Z). SB has received support from the NIHR and Wellcome Trust. MT is supported by the Dutch Epilepsy Foundation (NEF 14-19 & 19-08), ZonMW (Memorabel initiative), Dioraphte (2001 0403), E-RARE JTC 2018 (UltraAIE, 90030376505), and an Interlaken Leadership Award. FL and GK are supported by German Ministry of Education and Research (01GM1908A und 01GM2208, CONNECT-GENERATE), FL also by E-Rare Joint Transnational research support (ERA-Net, LE3064/2-1), Stiftung Pathobiochemie of the German Society for Laboratory Medicine and HORIZON MSCA 2022 Doctoral Network 101119457 — IgG4-TREAT.